Is Clearance of ctDNA an Acceptable Surrogate End Point?

Opinion
Video

Medical oncologists discuss whether ctDNA clearance can serve as an acceptable surrogate end point in the treatment of patients with colorectal cancer.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Related Content